Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
Japan’s FY2027 off-year drug price revision is effectively a settled matter, and there is no room for debate over whether it will be implemented, outspoken payer-side official Masato Matsumoto argued in a recent interview with Jiho. “At ministerial budget talks…
To read the full story
Related Article
ORGANIZATION
- Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
- FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
- FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
- JPMA Seeks Japan Version of EHDS to Unlock Life-Course Health Data
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…